Blocking the PD-1/PD-L1 pathway can normalize anti-tumor responses, but PD-1 inhibitors are not recommended to treat unselected DLBCL patients, due to low expression of PD-1/PD-L1 in DLBCL. The gene discussed is CD274; the disease is neoplasm.